{"success":true,"data":{"pressRelease":{"id":"147866","rtpr_id":"nBw9thw3Qa-20260919","ticker":"CLLS","exchange":"NASDAQ","all_tickers":["CLLS","ALCLS"],"title":"CLLS Investors Have Opportunity to Join Cellectis S.A. Fraud Investigation with SBS Law","author":"Business Wire","published_at":"2026-09-19T23:31:00.080Z","article_body":"CLLS Investors Have Opportunity to Join Cellectis S.A. Fraud Investigation\nwith SBS Law\n\nSchall, Brown & Schwartz\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fschallfirm.com%2F&esheet=54607375&newsitemid=20260919446999&lan=en-US&anchor=Schall%2C+Brown+%26amp%3B+Schwartz&index=1&md5=7c71b871cd04b8208f7d7953cdc75977)\nLLP (“SBS”), a national shareholder rights litigation firm, announces that\nit is investigating claims on behalf of investors of Cellectis S.A.\n(“Cellectis” or “the Company”) (NASDAQ: CLLS\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Ffinance.yahoo.com%2Fquote%2FCLLS&esheet=54607375&newsitemid=20260919446999&lan=en-US&anchor=CLLS&index=2&md5=2c72e8c8adef43b4127acafc52dd1221)\n) for violations of the securities laws.\n\nINVESTIGATION DETAILS: The investigation focuses on whether the Company issued\nfalse and/or misleading statements and/or failed to disclose information\npertinent to investors. Cellectis announced on September 14, 2026, that it\nwould prioritize in vivo gene editing therapies over CAR-T cell therapies. The\nCompany also announced the discontinuation of development of certain CAR-T\ncell therapies. The Company’s Chief Medical Officer stated, \"Cellectis is\nnot able finance [Eti-cel and Lasme-cel] given the time lines that we have and\nthe limited cash resources that we have.\" Based on this news, shares of\nCellectis fell by almost 41% on the same day.\n\nIf you are a shareholder who suffered a loss, click here to participate\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fschallfirm.com%2Fcases%2Fcellectis-s-a%2F&esheet=54607375&newsitemid=20260919446999&lan=en-US&anchor=click+here+to+participate&index=3&md5=72e4fbb0e4c8e8743f05ceb4b35b7630)\n.\n\nWe also encourage you to contact Brian Schall or David Schwartz of Schall,\nBrown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA\n90067, at 310-301-3335, to discuss your rights free of charge. You can also\nreach us through the firm's website at www.schallfirm.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fpr.report%2FmIwBkOrU&esheet=54607375&newsitemid=20260919446999&lan=en-US&anchor=www.schallfirm.com&index=4&md5=57daeb2cda5c80a36a448ce79ac35e0b)\n, or by email at david@schallfirm.com (mailto:david@schallfirm.com) .\n\nWHY SBS? Schall, Brown & Schwartz LLP represents investors around the\nworld and specializes in securities class action lawsuits and shareholder\nrights litigation. Bringing together the extensive experience and diverse\nskillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz,\nSBS is dedicated to aggressively advocating for every investor.\n\nThis press release may be considered Attorney Advertising in some\njurisdictions under the applicable law and rules of ethics.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260919446999/en/\n(https://www.businesswire.com/news/home/20260919446999/en/)\n\nSchall, Brown & Schwartz LLP\n\nBrian Schall, Esq.,\n\nAndrew Brown, Esq.,\n\nDavid Schwartz, Esq.,\n\nwww.schallfirm.com \n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.schallfirm.com&esheet=54607375&newsitemid=20260919446999&lan=en-US&anchor=www.schallfirm.com&index=5&md5=2c95898c5e022a4d0288c723caaef419)\n\nOffice: 310-301-3335\n\ninfo@schallfirm.com (mailto:info@schallfirm.com)\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw9thw3Qa-20260919","title":"CLLS Investors Have Opportunity to Join Cellectis S.A. Fraud Investigation with SBS Law","author":"Business Wire","ticker":"CLLS","created":"2026-09-19T23:31:00.080Z","tickers":["CLLS","ALCLS"],"exchange":"NASDAQ","article_body":"CLLS Investors Have Opportunity to Join Cellectis S.A. Fraud Investigation\nwith SBS Law\n\nSchall, Brown & Schwartz\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fschallfirm.com%2F&esheet=54607375&newsitemid=20260919446999&lan=en-US&anchor=Schall%2C+Brown+%26amp%3B+Schwartz&index=1&md5=7c71b871cd04b8208f7d7953cdc75977)\nLLP (“SBS”), a national shareholder rights litigation firm, announces that\nit is investigating claims on behalf of investors of Cellectis S.A.\n(“Cellectis” or “the Company”) (NASDAQ: CLLS\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Ffinance.yahoo.com%2Fquote%2FCLLS&esheet=54607375&newsitemid=20260919446999&lan=en-US&anchor=CLLS&index=2&md5=2c72e8c8adef43b4127acafc52dd1221)\n) for violations of the securities laws.\n\nINVESTIGATION DETAILS: The investigation focuses on whether the Company issued\nfalse and/or misleading statements and/or failed to disclose information\npertinent to investors. Cellectis announced on September 14, 2026, that it\nwould prioritize in vivo gene editing therapies over CAR-T cell therapies. The\nCompany also announced the discontinuation of development of certain CAR-T\ncell therapies. The Company’s Chief Medical Officer stated, \"Cellectis is\nnot able finance [Eti-cel and Lasme-cel] given the time lines that we have and\nthe limited cash resources that we have.\" Based on this news, shares of\nCellectis fell by almost 41% on the same day.\n\nIf you are a shareholder who suffered a loss, click here to participate\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fschallfirm.com%2Fcases%2Fcellectis-s-a%2F&esheet=54607375&newsitemid=20260919446999&lan=en-US&anchor=click+here+to+participate&index=3&md5=72e4fbb0e4c8e8743f05ceb4b35b7630)\n.\n\nWe also encourage you to contact Brian Schall or David Schwartz of Schall,\nBrown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA\n90067, at 310-301-3335, to discuss your rights free of charge. You can also\nreach us through the firm's website at www.schallfirm.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fpr.report%2FmIwBkOrU&esheet=54607375&newsitemid=20260919446999&lan=en-US&anchor=www.schallfirm.com&index=4&md5=57daeb2cda5c80a36a448ce79ac35e0b)\n, or by email at david@schallfirm.com (mailto:david@schallfirm.com) .\n\nWHY SBS? Schall, Brown & Schwartz LLP represents investors around the\nworld and specializes in securities class action lawsuits and shareholder\nrights litigation. Bringing together the extensive experience and diverse\nskillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz,\nSBS is dedicated to aggressively advocating for every investor.\n\nThis press release may be considered Attorney Advertising in some\njurisdictions under the applicable law and rules of ethics.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260919446999/en/\n(https://www.businesswire.com/news/home/20260919446999/en/)\n\nSchall, Brown & Schwartz LLP\n\nBrian Schall, Esq.,\n\nAndrew Brown, Esq.,\n\nDavid Schwartz, Esq.,\n\nwww.schallfirm.com \n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.schallfirm.com&esheet=54607375&newsitemid=20260919446999&lan=en-US&anchor=www.schallfirm.com&index=5&md5=2c95898c5e022a4d0288c723caaef419)\n\nOffice: 310-301-3335\n\ninfo@schallfirm.com (mailto:info@schallfirm.com)\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-09-19T23:31:00.120148259Z","server_sent_at_ms":1789860660120},"received_at":"2026-09-19T23:31:00.175Z","source_url":"https://www.businesswire.com/news/home/20260919446999/en/"},"analysis":{"id":"136669","press_release_id":"147866","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["Chief Medical Officer cited 'limited cash resources' — potential funding shortfall for lead CAR-T programs","Discontinuation of Eti-cel and Lasme-cel development announced due to financing constraints","Shares fell almost 41% on the September 14, 2026 pipeline pivot","Securities-fraud investigation signals potential disclosure-related liability"],"eventType":"legal_litigation","narrative":"Schall, Brown & Schwartz LLP, a national shareholder rights firm, announced it is investigating securities-law claims on behalf of Cellectis S.A. (NASDAQ: CLLS) investors and is soliciting shareholders who suffered losses to join the case.\n\nThe investigation stems from Cellectis's September 14, 2026 announcement that it would prioritize in vivo gene editing therapies over CAR-T cell therapies and discontinue development of certain CAR-T programs; the company's Chief Medical Officer stated Cellectis cannot finance Eti-cel and Lasme-cel given its timelines and limited cash resources.\n\nShares of Cellectis fell almost 41% on that announcement. This release itself is law-firm solicitation and attorney advertising, not a new disclosure from the issuer.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Law-firm solicitation following CLLS's 41% pipeline-pivot selloff — the underlying cash crunch is the real story; suppress the solicitation card."},"keyFigures":{"customDimensions":{"share_price_drop":"almost 41%","strategy_shift_date":"September 14, 2026"}},"quotedText":"Cellectis is not able finance [Eti-cel and Lasme-cel] given the time lines that we have and the limited cash resources that we have.","namedEntities":{"people":[{"name":"Brian Schall","role":"Founding partner, Schall, Brown & Schwartz LLP"},{"name":"Andrew Brown","role":"Founding partner, Schall, Brown & Schwartz LLP"},{"name":"David Schwartz","role":"Founding partner, Schall, Brown & Schwartz LLP"}],"products":["Eti-cel","Lasme-cel","in vivo gene editing therapies","CAR-T cell therapies"],"companies":[{"name":"Cellectis S.A.","ticker":"CLLS","relationship":"target of securities-law investigation"},{"name":"Schall, Brown & Schwartz LLP","relationship":"plaintiff law firm issuing solicitation"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"This is a plaintiff law-firm solicitation issued by Schall, Brown & Schwartz LLP ('SBS Law') seeking shareholders to join a securities-fraud investigation of Cellectis. No class has been certified and no settlement is announced; the underlying 41% share decline was already public news from the September 14, 2026 company announcement."},"tickerRelevance":{"others":[],"primary":"CLLS"},"globalImportance":16,"audienceRelevance":14,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap clinical-stage biotech","eventGravity":"law-firm-solicitation","issuerAuthored":false,"underlyingEvent":"41% share decline on CAR-T program discontinuation and financing constraints"}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Schall, Brown & Schwartz LLP, a national shareholder rights firm, announced it is investigating securities-law claims on behalf of Cellectis S.A. (NASDAQ: CLLS) investors and is soliciting shareholders who suffered losses to join the case.\n\nThe investigation stems from Cellectis's September 14, 2026 announcement that it would prioritize in vivo gene editing therapies over CAR-T cell therapies and discontinue development of certain CAR-T programs; the company's Chief Medical Officer stated Cellectis cannot finance Eti-cel and Lasme-cel given its timelines and limited cash resources.\n\nShares of Cellectis fell almost 41% on that announcement. This release itself is law-firm solicitation and attorney advertising, not a new disclosure from the issuer.","key_figures":{"customDimensions":{"share_price_drop":"almost 41%","strategy_shift_date":"September 14, 2026"}},"named_entities":{"people":[{"name":"Brian Schall","role":"Founding partner, Schall, Brown & Schwartz LLP"},{"name":"Andrew Brown","role":"Founding partner, Schall, Brown & Schwartz LLP"},{"name":"David Schwartz","role":"Founding partner, Schall, Brown & Schwartz LLP"}],"products":["Eti-cel","Lasme-cel","in vivo gene editing therapies","CAR-T cell therapies"],"companies":[{"name":"Cellectis S.A.","ticker":"CLLS","relationship":"target of securities-law investigation"},{"name":"Schall, Brown & Schwartz LLP","relationship":"plaintiff law firm issuing solicitation"}],"dollarAmounts":[]},"model_name":"glm-5.3-flash","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-19T23:31:19.379Z","global_importance":16,"audience_relevance":14,"importance_components":{"tickerTier":"small-cap clinical-stage biotech","eventGravity":"law-firm-solicitation","issuerAuthored":false,"underlyingEvent":"41% share decline on CAR-T program discontinuation and financing constraints"}},"durationMs":19194,"modelName":"glm-5.3-flash"}}